ZBAL:CA:TSX-BMO Balanced ETF (CAD)

ETF | Global Neutral Balanced |

Last Closing

CAD 39.35

Change

-0.03 (-0.08)%

Market Cap

CAD 0.25B

Volume

5.82K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Global Neutral Balanced

Symbol Name Price(Change) Market Cap
VBAL:CA Vanguard Balanced Portfolio

-0.08 (-0.25%)

CAD 3.09B
XBAL:CA iShares Core Balanced ETF Port..

-0.07 (-0.24%)

CAD 1.58B
VCNS:CA Vanguard Conservative ETF Port..

-0.04 (-0.14%)

CAD 0.51B
ZMI:CA BMO Monthly Income

-0.04 (-0.23%)

CAD 0.13B
PINC:CA Purpose Multi-Asset Income Fun..

N/A

CAD 0.07B
HCON:CA Global X Conservative Asset Al..

N/A

CAD 0.04B
PIN:CA Purpose Monthly Income Fund Se..

N/A

CAD 5.88M
PRP:CA Purpose Conservative Income Fu..

N/A

N/A

ETFs Containing ZBAL:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Global Neutral Balanced) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.75% 100% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.75% 100% F 48% F
Trailing 12 Months  
Capital Gain 19.10% 100% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.10% 100% F 50% F
Trailing 5 Years  
Capital Gain 25.24% 78% C+ 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.24% 78% C+ 53% F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.25B 63% D 49% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike